Search
Prasugrel
go.drugbank.com/drugs/DB06209ApprovedInvestigationalFDA approved in 2009. … Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary
Ravulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigationalIt is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. … [A244465] Ravulizumab was first approved by the FDA on December 21, 2018, for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in children and adults.
Rozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigational[L47122] It was granted orphan drug designation by the FDA in 2019, by the European Medicines Agency (EMA) in April 2020, and by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November … [A260207] AChR is vital for signal transduction in the neuromuscular junctions (NMJ) by generating muscle end plate potentials to propagate action potential.
XMT-1001
go.drugbank.com/drugs/DB06069InvestigationalXMT-1001 has demonstrated an improved therapeutic window as compared with CPT and irinotecan in human tumor xenografts models … In this novel CPT pro-drug, CPT is conjugated with a 70 kDa biodegradable hydrophilic polyacetal, poly (1-hydroxymethylene hydroxylmethylformal).
Categories: Compounds used in a research, industrial, or household settingFidanacogene elaparvovec
go.drugbank.com/drugs/DB16783ApprovedInvestigational[A32552] Disease severity is linked to the level of factor IX activity in the blood plasma, ranging from increased bleeding after injuries and surgical operations to spontaneous bleeding, hemorrhages in … from week 12 to month 15 compared to an ABR of 4.43 for the pre-treatment period.
Categories: Complex MixturesOseltamivir
go.drugbank.com/drugs/DB00198ApprovedInvestigationalNotably, in 2017, the World Health Organization downgraded oseltamivir from its essential medicines list from a "core" drug to a "complementary" drug, due to limited cost-effectiveness. … effect on hospitalizations, and that there was no evidence for any reductions in complications of influenza such as pneumonia.
Fremanezumab
go.drugbank.com/drugs/DB14041ApprovedInvestigational[L11749] It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. … [L11779] Along with other recently approved anti-CGRP therapies such as [galcanezumab], [erenumab], and the oral CGRP antagonist [ubrogepant], fremanezumab represents an important step forward in the treatment
Products: AJOVY SOLUTION FOR INJECTION IN PRE-FILLED PEN 225 MG/1.5ML, AJOVY SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 225 MG/1.5MLLurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalFood and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. … Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S.
Memantine
go.drugbank.com/drugs/DB01043ApprovedInvestigationalInitially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). … In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million.
Categories: N-methyl-D-aspartate Receptor AntagonistZavegepant
go.drugbank.com/drugs/DB15688ApprovedInvestigational[A258190,A258195] In March 2023, the FDA approved the use of zavegepant nasal spray for the acute treatment of migraine with or without aura in adults. … of oral zavegepant (150 mg bid) in subjects with mild allergic asthma.
Synonyms: 1-piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-n-((1r)-1-((7-methyl-1h-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-